Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + Carboplatin +/- Bevacizumab vs Chemotherapy in Platinum-sensitive Recurrent Ovarian Cancer
NCT07776171Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 3 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07776171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776171.